Examining genetics related to insulin and incretins in cystic fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the genetic factors associated with cystic fibrosis related diabetes (CFRD), focusing on the prevalence of specific genetic variants linked to Type 2 Diabetes Mellitus (T2DM). It aims to analyze insulin and incretin secretion in non-diabetic individuals with cystic fibrosis who possess either high-risk or low-risk genetic alleles. By collecting blood or saliva samples from participants aged 2 years and older, the study will assess the relationship between these genetic factors and glucose abnormalities in cystic fibrosis patients. The findings could enhance understanding of CFRD and its implications for patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Subjects age \>2y
2. Diagnosis of Cystic Fibrosis
3. For subjects\< 18 years, parental/guardian permission (informed consent) and if appropriate, child assent

Exclusion Criteria 1. Established diagnosis of non-CFRD (cystic fibrosis related diabetes) (e.g T1DM)

.

Where it's running

• The Children's Hopsital of Philadelphia
  Philadelphia, Pennsylvania, United States Recruiting
• The University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Andrea Kelly, MD — Children's Hospital of Philadelphia
• Study coordinator: Rachel Walega
• Email: walegar1@chop.edu
• Phone: 267-586-5969

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older

  This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07485543

• VX-272 dose escalation in healthy adults

  This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Tempe, Arizona · NCT07437105

• Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis

  This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07342920

• Dose escalation of VX-581 to check safety and drug levels in healthy adults

  The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Overland Park, Kansas · NCT07283770

• PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care

  This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.

  Recruiting CHU de Reims · Reims · NCT07274631

• Collecting sputum samples at home for cystic fibrosis patients

  This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.

  Recruiting at 4 sites University of Pennsylvania · Denver, Colorado and 3 other locations · NCT06950892

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.